Клинические исследования моноклональных антител против пропротеиновой конвертазы субтилизин-кексинового типа 9
Аннотация
В обзоре представлены данные современной научной литературы о различных фазах клинических исследований моноклональных антител против пропротеиновой конвертазы субтилизин-кексинового типа 9 (PCSK9). Приведены результаты законченных клинических исследований. Дан обзор клинических исследований, которые завершаются в 2015–2018 гг.
Об авторах
К. С. Астракова
ФГБНУ «НИИ терапии и профилактической медицины»
Россия
Россия
Ксения Сергеевна Астракова, аспирант
630089
ул. Бориса Богаткова, 175/1
Новосибирск
Ю. И. Рагино
ФГБНУ «НИИ терапии и профилактической медицины»
Россия
Россия
Юлия Игоревна Рагино, д-р мед. наук, проф., зав. лабораторией
лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний
630089
ул. Бориса Богаткова, 175/1
Новосибирск
Е. В. Шахтшнейдер
ФГБНУ «НИИ терапии и профилактической медицины»
Россия
Россия
Елена Владимировна Шахтшнейдер, канд. мед. наук, ведущий научный сотрудник
лаборатория молекулярно-генетических исследований терапевтических заболеваний
630089
ул. Бориса Богаткова, 175/1
Новосибирск
М. И. Воевода
ФГБНУ «НИИ терапии и профилактической медицины»
Россия
Россия
Михаил Иванович Воевода, д-р мед. наук, проф., член-корр., директор
630089
ул. Бориса Богаткова, 175/1
Новосибирск
Список литературы
1. Ridker P. M. LDL cholesterol: controversies and future therapeutic directions // Lancet. 2014. Vol. 384. P. 607–617.
2. Stein E. A., Mellis S., Yancopoulos G. D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol // N. Engl. J. Med. 2012. Vol. 366, N 12. P. 1108–1118.
3. Dias C. S., Shaywitz A. J., Wasserman S. M. et al. Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo- controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins // J. Am. Coll. Cardiol. 2012. Vol. 60, N 19. P. 1888–1898.
4. Clinical Trials gov. The Evaluation of PF-04950615 (RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). – http://clinicaltrials.gov/ct2/show/NCT01975389?termјSPIRE-2&rankј1, Published March 4, 2014 (accessed 19. 03. 14.).
5. Mason I. Pharma Times on line, Antibody lipid treatments enter final furlong. – https://www.pharmatimes.com/news/antibody_lipid_treatments_enter_final_furlong_1005620
6. Dadu R. T., Ballantyne C. M. Lipid lowering with PCSK9 inhibitors // Nat. Rev. Cardiol. 2014. Vol. 84. P. 1–13.
7. Ecker-Schlipf B. Hyperlipidemia. New treatment option with Evolocumab // Med. Monatsschr. Pharm. 2014. Vol. 37, N 7. P. 271–272.
8. Chan J. C., Piper D. E., Cao Q. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9820–9825.
9. Stein E. A., Honarpour N., Wasserman S. M. et al. Effect of the, proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia // Circulation. 2013. Vol. 128, N 19. P. 2113–2120.
10. Raal F., Scott R., Somaratne R. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial // Circulation. 2012. Vol. 126, N 20. P. 2408–2417.
11. Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.
12. Koren M. J., Scott R., Kim J. B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexintype 9 as monotherapy in patients with hypercholesterolaemia(MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study // Lancet. 2012. Vol. 380, N 9858. P. 1995–2006.
13. Giugliano R. P., Desai N. R., Kohli P. et al. Efficacy, safety, and tolerability of amonoclonal antibody to proprotein convertase subtilisin/ kexin type 9 in combination with a statin in patients with hypercho lesterolaemia(LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study // Ibid. P. 2007–2017.
14. Koren M. J., Giugliano R. P., Raal F. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial // Circulation. 2014. Vol. 129, N 2. P. 234–243.
15. Hirayama A., Honarpour N., Yoshida M. et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in Hypercholesterolemic, statin-treated japanesepatients at high cardiovascular risk // Circ. J. 2014. Vol. 78, N 5. P. 1073–1082.
16. Sahebkar A., watts G. F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes // Clin. Ther. 2013. Vol. 35, N 8. P. 1082–1098.
17. Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.
18. Stroes E., Colquhoun D., Sullivan D. et al. Anti-PCSK9 antibodyeffectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placeboc ontrolled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2541–2548.
19. Koren M. J., Lundqvist P., Bolognese M. et al. Anti-PCSK9 monotherapy for hypercholesterolemia – the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2531–2540.
20. Raal F. J., Honarpour N., Blom D. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial // Lancet. 2015. Vol. 385. P. 341–350.
21. Blom D. J., Hala T., Bolognese M. et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia // N. Engl. J. Med. 2014. Vol. 370, N 19. P.1809–1819.
22. Trial assessing long term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG). http://clinicaltrials.gov/show/NCT01624142 (accessedAug 9, 2014).
23. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633 (accessed Aug 9, 2014).
24. Global Assessment of Plaque regression With a PCSK9 antibody as Measured by intravascular Ultrasound (GLAGOV). https://clinicaltrials.gov/ct2/show/NCT01813422.
25. Gusarova V., Howard V. G., Okamoto H. et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates // Clin. Lipid. 2012.
26. Schaefer H., Falk E., Herling A. W. et al. Cholesterollowering effect of SAR236553/REGN727 in hamster after single s. c. injection // Drugs affecting lipid metabolism XVII international symposium e diabetes, obesity and the metabolic syndrome. Doha: Qatar. 2011. March. P. 14–16.
27. Roth E. M., McKenney J. M., Hanotin C. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367, N 20. P. 1891–1900.
28. Robinson J. G., Farnier M., Krempf M. et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in 2,341 high cardiovascular risk patients: ODYSSEY LONG TERM // Latebreaking trial presentation at the American Heart Association 2014 Scientific Sessions.
29. Moriarty P. M., Thompson P. D., Cannon C. P. et al. ODYSSEY ALTERNATIVE: Efficacy and safety of the proprotein convertasesubtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm // Ibid.
30. Bays H., Farnier M., Weiss R. et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II // Ibid.
31. Schwartz G. G., Bessac L., Berdan L. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial // Am. Heart J. 2014. Vol. 168, N 5. P. 682–689.
32. Ballantyne Ch. M., Neutel J., Cropp A. et. al. Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia // Am. J. Cardiol. 2015. Vol. 115, N 9. P. 1212–1221.
33. Marais A. D., Kim J. B., Wasserman S. M., Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels // Pharmacology & Therapeutics. 2015. Vol. 145. P. 58–66.
Рецензия
Для цитирования:
Астракова К.С., Рагино Ю.И., Шахтшнейдер Е.В., Воевода М.И. Клинические исследования моноклональных антител против пропротеиновой конвертазы субтилизин-кексинового типа 9. Атеросклероз. 2015;11(2):43-49.
For citation:
Astrakova K.S., Ragino Yu.I., Shakhtshneider E.V., Voevoda M.I. Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9. Ateroscleroz. 2015;11(2):43-49. (In Russ.)
Просмотров:
320
Послать статью по эл. почте 